Back to News
Market Impact: 0.3
Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus
Source: Nasdaq
Trade Policy & Supply ChainEnergy Markets & PricesHealthcare & BiotechInvestor Sentiment & Positioning
U.S. stocks came under pressure Tuesday as heightened U.S.-Canada trade tensions and rising oil prices weakened investor sentiment. The SPDR S&P Biotech ETF (XBI), a broad U.S. biotechnology-sector benchmark, declined, although the article text does not provide the magnitude of the move.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
More News
- AI Debt Binge Is Reordering Risk Hierarchy With Emerging Bonds
- CNBC Daily Open: Apple's new iPhone bends. Bond vigilantes, not so much
- Brent holds above $100 as tanker attacks deepen supply fear
- Asia stocks slip on tech losses with oil surge, yields in focus
- Asian stocks wilt as Brent holds above $100, yields near 2023 peak
- Currency markets subdued as oil shock lifts global yields; ECB, U.S. inflation eyed